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 Abstract 
Insomnia is one of the most frequently reported and debilitating difficulties 
associated with cancer.  Recent decades have seen a move from pharmacological 
interventions for insomnia, to non-pharmacological, cognitive behavioural therapies 
(CBT-I).  Numerous clinical trials have established the effectiveness of CBT-I in the 
general population and more recently, in those with insomnia associated with 
cancer.  However, despite these promising outcomes, the availability of such 
therapies remains limited across cancer services.  Recent years have seen 
developments to widen access to CBT-I, including the use of internet-based 
resources.  Such developments may offer a useful means of overcoming the 
availability and access issues of CBT-I for those with insomnia associated with 
cancer. 
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Introduction 
Despite its pervasiveness and chronicity, insomnia in cancer care is under-
reported by patients, overlooked by clinicians and as a consequence, poorly 
managed. This is partly due to the belief that insomnia is a transient response to 
cancer diagnosis and treatment, which will self-resolve. However, insomnia which 
remains untreated has consequences for psychological and physical wellbeing. 
Diminished quality of life, impaired mood, heightened pain and increased fatigue are 
all common responses to persistent insomnia disorder, and many of those living with 
cancer experience unremitting insomnia which impacts upon daytime functioning. 
Evidence demonstrates that cognitive behaviour therapy (CBT) should be the first-
line intervention for insomnia disorder and patients have expressed their acceptance 
of this treatment approach. However, despite this evidence, CBT is not routinely 
available to cancer populations, perhaps due to uncertainty around when and how it 
could most usefully be made available.  
 
Cancer and insomnia prevalence 
According to the World Health Organisation, cancer is among the leading 
causes of morbidity and mortality worldwide. Approximately 14 million new cases 
were recorded in 2012 and this figure is expected to rise by around 70% over  the 
next 2 decades (1). In particular, breast cancer incidence has increased from a rate 
of 103/100,000 in 1975 to 126/100,000 in 2007 and there is an increased incidence 
of colorectal cancer in developed countries (2). Both breast and colorectal cancers 
have been linked to circadian disruption (3) and their epidemiology correlates with 
regions where circadian disruption, through night-shift working, for example, is most 
prevalent (4). Although tentative, this evidence may suggest a circadian disruption-
based model for cancer, particularly breast and colorectal cancers, which should be 
further explored. 
Fortunately, due to screening programmes, earlier disease detection and 
improving treatment regimes, cancer survival rates are also increasing. Recent 
estimates indicate that around half of those diagnosed with cancer are expected to 
survive for at least 10 years and in the UK alone, cancer survival rates have doubled 
in the last 40 years (5) However these improvements in rates of survivorship are not 
without cost. Evidence shows that many cancer survivors experience a significant 
symptom burden (3), particularly at the end of active treatment when treatment side 
effects often fail to remit (4). 
One of the most commonly reported side effects of cancer diagnosis / 
treatment is insomnia, which refers to difficulty initiating or maintaining sleep at least 
three nights per week for at least three months, accompanied by impaired daytime 
functioning (5). Epidemiological data from cancer populations report that 25-69% 
report difficulty sleeping, with 18-29% reporting sleep disturbance that meets 
diagnostic criteria for insomnia disorder (9±11). However, despite increasing 
awareness of the pervasiveness of insomnia within cancer groups, scientific reports 
of insomnia prevalence remain variable and wide-ranging. This is partly due to the 
utilisation of different insomnia definitions, measurements and timing of assessments 
(8). However, recent amendments to the diagnostic criteria for insomnia disorder (8) 
and the publication of clinical screening tools based upon these new criteria (12) 
should result in improvements to the consistency of prevalence estimates in future 
studies. 
 
Evolution of insomnia in cancer 
Although insomnia is a prevalent problem for cancer patients, little information is 
available about its long-term course and limited studies have focused on insomnia as 
a persistent disorder in oncology groups. However, scientific understanding of the 
evolution of insomnia has been applied in the context of cancer, and etiological 
factors including insomnia predisposition, precipitation and perpetuation have been 
proposed (13). One recent report on the natural history of insomnia in cancer 
patients reported data on incidence, persistence, remission and relapse of insomnia 
over the 18-month period following diagnosis in a group of patients with mixed 
cancer types (11). The study revealed high rates of insomnia at baseline (59%), 
including 28% with insomnia disorder. Insomnia became less prevalent over the 18-
month assessment period but did remain pervasive at the end of the study (36%). 
Approximately 15% of patients experienced a first incidence of insomnia during the 
study and around 20% experienced relapse. Patients categorised as having an 
insomnia disorder were much less likely to experience remission than those who had 
insomnia symptoms. Those meeting criteria for insomnia disorder at baseline 
retained that sleep status for the duration of the study, highlighting its persistence 
over time. This study provides a useful analysis of the evolution of insomnia disorder 
during the cancer diagnosis / treatment / rehabilitation phases and indicates the 
point(s) at which cancer patients may be most vulnerable to developing a persistent 
complaint of poor sleep. 
The elevated prevalence of insomnia amongst cancer patients is partly explained 
by heightened psychological distress following diagnosis (15). However, the side-
effects from active cancer treatment are also known to contribute to the deterioration 
of good sleep (16±18). A large scale prospective study of cancer patients undergoing 
chemotherapy, found that 39.8% reported moderate or severe insomnia symptoms 
after their initial chemotherapy session. Furthermore, two-thirds of patients reported 
that insomnia symptoms persisted throughout their subsequent cycles of 
chemotherapy (9). In particular, sleep maintenance problems are the most frequently 
reported sleep complaint during active treatment, with 63.3% of patients 
experiencing fragmented sleep patterns (19).   
Once established, insomnia often becomes a chronic, unremitting complaint. 
RCT data from a cancer survivor population reported a median insomnia duration of 
greater than 2 years (20). Similarly, a cross-sectional survey of 982 cancer patients 
found that 31% reported insomnia, of which 75% had a chronic disorder (i.e., lasting 
six months or more). Therefore, it seems that insomnia often takes a chronic course 
in many cancer patients (21). This pattern of persistence may be explained by 
individual responses to sleep disturbance that influence its maintenance over time 
(e.g. maladaptive sleep behaviour, faulty beliefs). These individual responses are 
potentially more commonly observed in cancer populations than in the general 
population, due to their focus on restoration and recovery. In order to cope with the 
physical demands of active treatment (i.e. surgery, chemotherapy, radiotherapy), 
cancer patients may be required to rest more than usual during the day. Qualitative 
reports from cancer survivor populations indicate that they implement earlier 
bedtimes, later rising times and increased daytime napping during their cancer 
treatment (22) . These maladaptive sleep habits encourage the development of an 
irregular sleep-wake pattern, which may ultimately lead to de-synchronisation of the 
sleep-wake cycle and contribute to the development of a chronic insomnia disorder 
(13). Therefore, disease-specific factors (such as psychological distress, active 
cancer treatment) may contribute to the precipitation of insomnia, whilst poor sleep 
behaviours arising as a result of attempts to combat these disease specific factors, 
may contribute to its maintenance. 
 
Consequences of insomnia in cancer 
Insomnia disorder is not only prevalent and persistent, but is consequential for 
both psychological and physical wellbeing. Research indicates that good sleep 
quality, characterised by consistent and distinguishable sleep/wake patterns, 
reduces depressive symptomatology, enhances quality of life and improves physical 
outcomes (23±25). However, due to the high prevalence of insomnia following 
diagnosis, cancer patients are especially vulnerable to the negative impact of sleep 
disruption. Also, insomnia often occurs alongside other symptoms like fatigue, 
anxiety and low mood (18,26±28), causing further impairment to quality of life. Liu et 
al found that breast cancer patients who reported multiple symptoms (symptom 
clusters) prior to the onset of active treatment, experienced poorer sleep, more 
fatigue and reduced mood during cancer treatment (26). Therefore one symptom 
may contribute to the maintenance and exacerbation of the others (29).  
Associations between commonly occurring symptoms have also been 
explored in the general population. For example, epidemiological data indicates that 
insomnia contributes to the development of depressive disorder (27) and individuals 
with cancer and insomnia experience reduced functioning, increased pain and more 
fatigue than those without insomnia (30,31). Sharma et al, reported that almost one 
third of cancer patients described sleep problems reaching clinical levels, which were 
strongly related to symptoms of psychological distress (28). Therefore, given the 
increasing number of cancer survivors who are likely to have comorbid symptoms 
(including insomnia), there is a considerable burden on healthcare providers to 
understand and implement symptom management strategies to cope with these 
increasing demands.  
 
Cognitive Behaviour Therapy for insomnia (CBT-I) in cancer 
The consequences of insomnia can be severe enough to warrant medical 
intervention, with 25% of cancer patients regularly taking sleeping tablets. However, 
this long term pharmacotherapy is undesirable to patients (32). There is considerable 
evidence that intervening at the psychosocial level, using cognitive behavioural 
therapy, is effective for insomnia associated with cancer (20,33±40) and is a 
treatment approach that patients prefer (22).  
Cognitive behavioural therapy for insomnia (CBT-I) is a multicomponent 
intervention that was developed to target the specific cognitive, physiological and 
behavioural aspects that characterise the insomnia disorder. Essentially, CBT-I 
comprises five potential elements, including stimulus control, sleep restriction, sleep 
hygiene, cognitive restructuring and relaxation training. Evidence demonstrates that 
CBT-I can be successfully administered using a range of delivery methods, including 
groups (41,42), telephone (43), online (44,45)  and self-help manuals (46). 
Importantly, the effectiveness of CBT-I has been demonstrated for insomnia that 
occurs alongside complex psychiatric and medical conditions as well as for insomnia 
without those comorbidities. 
To date, nine controlled trials of CBT-I in cancer patients have been 
conducted (summarised in Table I) (20,33,35±40,47±49). The largest of these trials 
using face-to-face CBT-I was conducted by Espie et al (2008) (20). This study 
recruited 150 cancer patients (mixed tumour sites) to either a group delivered, nurse 
led CBT-I intervention or to a treatment as usual (TAU) condition. Significant 
improvements in subjectively reported sleep onset latency, wake time after sleep 
onset and sleep efficiency were noted in the CBT-I group, with large between-group 
effect sizes of -0.86, -0.97, and 1.09, respectively. These results represented a 
reduction of approximately 1 hour in sleep onset latency and time spent awake 
during the night. There was no change in the TAU group and results were sustained 
at 6 month follow-up assessment. Alongside these improvements in sleep outcomes, 
improvements to quality of life, mood and levels of cancer-related fatigue were also 
reported in the CBT-I condition (29).  
 
Table 1 here 
 
 
Recent Advances in CBT Delivery 
Although numerous studies have identified CBT as an effective and well-tolerated 
therapy for insomnia associated with cancer, this therapeutic approach is not always 
widely available to patients. Limited availability of therapists with sufficient expertise 
and geographical distance from treatment centres can prove to be barriers.  This is 
something that is not limited to those with cancer: treatment for sleep disorders in 
general is often piece-meal across services (50). However, a concomitant physical 
illness can bring with it further difficulties in accessing treatment.  The diagnosis of 
cancer can bring significant financial burdens, meaning that the cost of additional 
travel to treatment centres may be prohibitive (51). Furthermore, the physical effects 
of both the illness and its treatment may preclude others from seeking additional 
treatment. 
The issues of availability and access have been explored widely in the general 
literature for psychological therapies, with increasing attempts, over recent decades, 
to train non-psychologists to deliver psychological therapies.  In particular, attention 
has been paid to developing the skills of nursing members of the multi-disciplinary 
health team (52). A similar process has taken place within the general insomnia 
literature, with a substantial focus on widening access to CBT for insomnia through 
dissemination of treatment programmes to a wider pool of health professionals, such 
as community nursing staff (53). Such efforts provide a wider pool of therapists, 
thereby increasing the availability of the therapy and potentially, reducing the cost of 
delivery.  A further step in this process has been the use of guided self-help 
materials (often utilising the internet) as a means of delivering psychological 
therapies.  Positive outcomes for these have been found in the general literature for 
psychological disorders, as well as in studies specific to insomnia (44,54,55). The 
availability of differing treatment delivery methods allows the opportunity for a 
stepped-care model of care within services, thereby increasing access and reducing 
costs (50).  
Similar trends in the delivery of CBT for insomnia associated with cancer have 
emerged in recent years, with studies exploring options for providing psychological 
treatment to individuals with cancer and sleep disorders.  The composition of these 
interventions typically involves a series of treatment sessions, with material that 
covers the same areas as would be provided in face-to-face treatment.  The 
difference in these cases is that treatment is delivered at distance, either through 
video-recorded sessions (50), or through on-line sessions (35). In SaYDUG HW DO¶s 
(2014) study, the opportunity for telephone contact with a therapist was available, but 
somewhat surprisingly, only a limited number (8%) of participants chose to do this. 
This study established that video-based self-help materials can have significant 
benefits in resolving symptoms of insomnia associated with cancer (48), albeit that 
outcomes for remission rates and relapse rates (for insomnia) were poorer in the 
video-based treatment group, than a comparison face-to-face group.  Ritterberg et al 
(2012) also found evidence of efficacy in the use of their internet-based therapy, to 
an extent that matched those found in studies of face-to-face delivered therapy with 
cancer survivors (35).  Although it is acknowledged that aspects of direct treatment 
(in particular, the therapeutic relationship) may be difficult to recreate in distance 
methods, the accessibility and cost benefits of such models should not be 
discounted.  Indeed, for many individuals, the only viable treatment option would be 
through distance methods. &OHDUO\ WKH FRXQWHUEDODQFH WR WKLV ZLOO EH LQGLYLGXDOV¶
access to the necessary technology, such as internet connections, and the ease of 
use of programmes. Nonetheless, work to overcome these barriers and explore this 
additional treatment modality is likely to be a focus of research in future years.   
 
 
Conclusion 
A clear focus on informing the implementation of CBT for insomnia as part of 
general psychological care within the oncology settings should be a research priority. 
In current clinical practice, the only help available for the troubling, chronic problem 
of insomnia has been the attempted short term fix of hypnotic medication, which 
most cancer patients find particularly undesirable (22). However, CBT for insomnia is 
an evidence-based solution that is not only safe and effective, but also has the 
potential to make long term improvements to health and wellbeing in cancer 
populations. 
CBT is an effective and enduring treatment for chronic insomnia disorder, but so 
far the evidence for CBT has not changed practice. Uncertainty remains about how 
CBT for insomnia could be integrated into existing oncology care settings, 
specifically with regard to when it would be most useful for the patient.  However, it is 
suggested that the most substantive barrier to integration of CBT for insomnia into 
practice is availability. Therapist availability, geographical distance and financial 
resource implications may limit patient access to treatment.  
Recent years have seen the development of several models of treatment delivery 
for CBT for insomnia. This provides the potential for a stepped-care model, 
something that may be key to increasing integration of insomnia treatment within 
wider cancer services. Moving forward, the research focus must be to improve the 
management of severe and intrusive sleep disturbance that is common in cancer by 
determining the methods by which it would be most suitable to provide CBT 
intervention to these patients.  
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